EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0
- PMID: 39387894
- PMCID: PMC11732780
- DOI: 10.1007/s00259-024-06915-3
EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0
Abstract
Introduction: Hybrid [18F]FDG PET imaging is currently the method of choice for a wide variety of infectious and inflammatory disorders and was recently adopted in several clinical guidelines. A large amount of evidence-based articles, guidelines and appropriate use criteria have been published since the first version of this guideline in 2013.
Purpose: To provide updated evidence-based information to assist physicians in recommending, performing and interpreting hybrid [18F]FDG PET examinations for infectious and inflammatory disorders in the adult population.
Methods: A systematic literature search of evidence-based articles using whole-body [18F]FDG hybrid imaging on the indications covered within this guideline was performed. All systematic reviews and meta-analyses published within the last 10 years until January 2023 were identified in PubMed/Medline or Cochrane. For each indication covered in this manuscript, diagnostic performance was provided based on meta-analyses or systematic reviews. If not available, results from prospective or retrospective studies were considered based on predefined selection criteria. RESULTS AND CONCLUSIONS: Hybrid [18F]FDG PET is extremely useful in the work-up and management of adults with infectious and inflammatory diseases, as supported by extensive and rapidly growing evidence-based literature and adoption in clinical guidelines. Practical recommendations are provided describing evidence-based indications as well as interpretation criteria and pitfalls. Monitoring treatment response is the most challenging but insufficiently studied potential application in infection and inflammation imaging.
Keywords: Guideline; Infection; Inflammation; PET/CT; Procedure standard; [18F]FDG.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethics approval: This guideline did not involve human participants or animals, and hence was exempt from institutional review board approval. Consent to participate: Not applicable. Consent to publish: Not applicable. Conflicts of interest: Authors Mike Machaba Sathekge, Ora Israel, and Arturo Chiti are editors of this journal. GA: Novartis – Advanced Accelerator Applications- speaker honoraria GT: nothing to disclose MP-G: supported by a Fonds de recherche du Québec – Santé (FRQ-S) clinical research scholar award JB: nothing to disclose AC: Novartis – Advanced Accelerator Applications, advisory boards and speaker honoraria; Sirtex, speaker honorarium; General Electric Healthcare, speaker honorarium; Telix, advisory board; Bracco, speaker honorarium; European Journal of Nuclear Medicine and Molecular Imaging, Editor in Chief EHD: nothing to disclose AWJMG: nothing to disclose CJP: nothing to disclose MS: nothing to disclose AS: nothing to disclose FJ: nothing to disclose OI: GE Healthcare- consultant OG: nothing to disclose
References
-
- Vaidyanathan S, et al. FDG PET/CT in infection and inflammation–current and emerging clinical applications. Clin Radiol. 2015;70:787. - PubMed
-
- Jamar F, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647. - PubMed
-
- Kirienko M, et al. Hybrid PET/MRI in Infection and Inflammation: An Update About the Latest Available Literature Evidence. Semin Nucl Med. 2023;53:107. - PubMed
-
- Durack DT, Street AC. Fever of unknown origin–reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
